Information  X 
Enter a valid email address

Star Phoenix Group (STA)

  Print   

Wednesday 05 August, 2020

Star Phoenix Group

Update on the proposed EGM

RNS Number : 1995V
Star Phoenix Group Ltd
05 August 2020
 

Star Phoenix Group Ltd

("Star Phoenix" or "the Company")

 

5 August 2020

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE ("RIS"), THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. 

 

UPDATE ON THE PROPOSED EGM

Following announcements on 27 and 29 July 2020, the Company advises that the Directors of the Company have accepted the validity of the notices under section 249D of the Australian Corporations Act 2001 received from Thesolia Ltd and Beijing Sibo Investment Management LP.

The Company has commenced the necessary preparations to call a general meeting to consider the following resolutions:

1.  Removal of Director - Dr. YuFeng Meng;

2.  Election of Director - Dr. Yang Chong Yi;

3.  Election of Director - Mr. Paul Norris;

4.  Election of Director - Mr. Omar C.S. Stanford IV;

5.  Election of Director - Mr. Li Jun;

6.  Removal of Director - Mr. Zhiwei (Kerry) Gu; and

7.  Removal of Director - Mr. Lubing Liu.

Further details will be provided in the notice of meeting to be published no later than 17 August 2020.

This announcement has been approved by Chairman Kerry Gu on behalf of the Company.

 

Contact Details

 


 

Star Phoenix Group Ltd

Evgenia Bezruchko (Group Corporate Development Manager & Joint Company Secretary)

e. [email protected]

t.   +44 (0)20 3865 8430

WH Ireland Limited (Nominated Adviser and Broker)

James Joyce / Matthew Chan

t.   +44 (0)20 7220 1666

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
FURFIFVDTTIEIII

a d v e r t i s e m e n t